Sino Biopharmaceutical (SMZ1) AI Stock Analysis

0 Followers

Sino Biopharmaceutical

(BX Swiss:SMZ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Reaccelerating Revenue GrowthImproving top-line growth indicates stronger demand and commercialization across the medicine portfolio after several slower periods. If sustained, this momentum can broaden the revenue base, support operating leverage, and provide resources for continued investment in research, approvals, and market expansion.

Negative Factors

Falling Net ProfitabilityThe sharp decline in net margin shows that revenue growth is not translating into bottom-line earnings as efficiently as before. Persistent pressure could reduce reinvestment capacity, weaken returns on equity, and make future earnings less predictable even if the company maintains strong gross margins.

Sino Biopharmaceutical (SMZ1) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 11.84B
Dividend Yield: 1.87%
Average Volume (3M): ―
Price to Earnings (P/E): 36.3
Beta (1Y): -0.67
Revenue Growth: 4.45%
EPS Growth: -38.06%
Country: Switzerland
Employees: 22,838
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Sino Biopharmaceutical Business Overview & Revenue Model

Company Description

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicin...

Sino Biopharmaceutical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:SMZ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1530	80Outperform	HKD 38.41B	3.83	30.16%	1.67%	101.73%	249.15%
HK:1801	72Outperform	HKD 154.34B	104.31	6.06%	―	42.64%	9.67%
HK:2696	65Neutral	HKD 27.35B	26.69	20.41%	―	32.63%	8.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:9926	48Neutral	HKD 83.86B	-70.81	-10.86%	―	42.47%	-15.80%
HK:1877	41Neutral	HKD 32.01B	-73.23	-7.23%	―	35.82%	54.40%

* Healthcare Sector Average

Performance Comparison

CH:SMZ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:SMZ1	Sino Biopharmaceutical	0.58	0.07	12.89%
HK:1801	Innovent Biologics	86.80	-5.15	-5.60%
HK:1530	3SBio, Inc.	14.97	-18.32	-55.03%
HK:9926	Akeso, Inc.	88.60	-32.90	-27.08%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.67	-10.63	-40.42%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.88	-14.87	-22.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sino Biopharmaceutical AI Stock Analysis